Today's Daily Dose brings you news about Moderna moving its COVID-19 vaccine candidate into phase III testing, Pfizer/BioNTech selecting BNT162b2 vaccine candidate for SARS COV-2 to advance into phase II/III trial, positive results from TCR2 Therapeutics' phase I/II trial of TC-210 for mesothelin-expressing solid tumors, and Spectrum Pharma's non-small cell lung cancer trial results.
from RTT - Biotech https://ift.tt/3jO2Ztl
via IFTTT
No comments:
Post a Comment